Gabapentin in traumatic nerve injury pain: A randomized, double-blind, placebo-controlled, cross-over, multi-center study
Authors:
- Torsten E. GordhTGTorsten E. Gordh
- Audun StubhaugASAudun Stubhaug
- Troels S. JensenTJTroels S. Jensen
- Staffan ArnèrSAStaffan Arnèr
- Björn BiberBBBjörn Biber
- Jörgen BoivieJBJörgen Boivie
- Clas MannheimerCMClas Mannheimer
- Jarkko KalliomäkiJKJarkko Kalliomäki
- Eija KalsoEKEija Kalso
- 31 August 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Pain
- Vol. 138 (2) , 255-266
Abstract
A double-blind, randomized, placebo-controlled cross-over multi-center study was conducted to evaluate the efficacy and safety of gabapentin in the treatment of neuropathic pain caused by traumatic or postsurgical peripheral nerve injury, using doses up to 2400 mg/day. The study comprised a run-in period of two weeks, two treatment periods of five weeks separated by a three weeks' washout period. The primary efficacy variable was the change in the mean pain intensity score from baseline to the last week of treatment. Other variables included pain relief, health related quality of life (SF-36), interference of sleep by pain, Clinician and Patient Global Impression of Change, and adverse effects. Nine centers randomized a total of 120 patients, 22 of whom withdrew. There was no statistically significant difference between the treatments for the primary outcome efficacy variable. However, gabapentin provided significantly better pain relief (p=0.015) compared with placebo. More patients had at least a 30% pain reduction with gabapentin compared with placebo (p=0.040) and pain interfered significantly less with sleep during gabapentin treatment compared with placebo (p=0.0016). Both the Patient (p=0.023) and Clinician (p=0.037) Global Impression of Change indicated a better response with gabapentin compared with placebo. Gabapentin was well tolerated. The most common adverse effects were dizziness and tiredness.Keywords
This publication has 30 references indexed in Scilit:
- Algorithm for neuropathic pain treatment: An evidence based proposalPain, 2005
- Core outcome measures for chronic pain clinical trials: IMMPACT recommendationsPain, 2005
- A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathiesJournal of Neurology, 2004
- EFNS guidelines on neuropathic pain assessmentEuropean Journal of Neurology, 2004
- Genotype-dependence of gabapentin and pregabalin sensitivity: the pharmacogenetic mediation of analgesia is specific to the type of pain being inhibitedPain, 2003
- Pregabalin for the treatment of postherpetic neuralgiaNeurology, 2003
- Inhibition of neuronal Ca2+ influx by gabapentin and pregabalin in the human neocortexNeuropharmacology, 2002
- Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scalePain, 2001
- Gabapentin for the Symptomatic Treatment of Painful Neuropathy in Patients With Diabetes MellitusA Randomized Controlled TrialJAMA, 1998
- The Novel Anticonvulsant Drug, Gabapentin (Neurontin), Binds to the α2δ Subunit of a Calcium ChannelJournal of Biological Chemistry, 1996